Aurora Cannabis (ACB) Aktienübersicht
Aurora Cannabis Inc. ist zusammen mit seinen Tochtergesellschaften in der Produktion, dem Vertrieb und dem Verkauf von Cannabis und Cannabisderivaten in Kanada und international tätig. Mehr Details
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 4/6 |
| Künftiges Wachstum | 0/6 |
| Vergangene Leistung | 0/6 |
| Finanzielle Gesundheit | 5/6 |
| Dividenden | 0/6 |
ACB Community Fair Values
Create NarrativeSee what 54 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Aurora Cannabis Inc. Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | CA$4.73 |
| 52-Wochen-Hoch | CA$9.33 |
| 52-Wochen-Tief | CA$4.29 |
| Beta | 1.34 |
| 1 Monat Veränderung | 1.94% |
| 3 Monate Veränderung | -3.47% |
| 1 Jahr Veränderung | -41.82% |
| 3 Jahre Veränderung | -38.57% |
| 5 Jahre Veränderung | -95.85% |
| Veränderung seit IPO | -91.24% |
Aktuelle Nachrichten und Updates
Narrativ-Update • Jun 05
ACB: Rescheduling Tailwinds And Medical Portfolio Expansion Will Shape Balanced Outlook
Analysts have adjusted their CA$ price target on Aurora Cannabis to reflect updated expectations for slightly improved revenue trends, a higher profit margin outlook, and a lower future P/E, supported in part by recent Street research that views partial cannabis rescheduling as extremely favorable for the sector. What's in the News Aurora Cannabis received Plant Breeders' Rights in Canada for two proprietary cultivars, Farm Gas and Driftwood Diesel, giving the company exclusive rights to grow, propagate, and sell products from these varieties across key medical markets.Narrativ-Update • May 09
ACB: Partial Rescheduling And Medical Portfolio Shifts Will Shape Balanced Outlook
Analysts have revised their Aurora Cannabis price target to CA$5.00 from CA$5.00, citing updated views on regulatory progress around partial cannabis rescheduling and its potential implications for the company’s risk profile and long term earnings power. Analyst Commentary Recent commentary highlights that partial cannabis rescheduling is viewed as extremely favorable for the sector, but bearish analysts remain cautious on how much of that potential is already reflected in Aurora Cannabis' valuation at the current CA$5.00 price target.Narrativ-Update • Apr 20
ACB: Reset P E Multiple And Equity Issuance Will Shape Balanced Outlook
Analysts have reduced their CA$ price target on Aurora Cannabis by CA$1. This change reflects updated views on profit margins, revenue trends, and a lower assumed future P/E multiple.Recent updates
Narrativ-Update • Jun 05
ACB: Rescheduling Tailwinds And Medical Portfolio Expansion Will Shape Balanced Outlook
Analysts have adjusted their CA$ price target on Aurora Cannabis to reflect updated expectations for slightly improved revenue trends, a higher profit margin outlook, and a lower future P/E, supported in part by recent Street research that views partial cannabis rescheduling as extremely favorable for the sector. What's in the News Aurora Cannabis received Plant Breeders' Rights in Canada for two proprietary cultivars, Farm Gas and Driftwood Diesel, giving the company exclusive rights to grow, propagate, and sell products from these varieties across key medical markets.Narrativ-Update • May 09
ACB: Partial Rescheduling And Medical Portfolio Shifts Will Shape Balanced Outlook
Analysts have revised their Aurora Cannabis price target to CA$5.00 from CA$5.00, citing updated views on regulatory progress around partial cannabis rescheduling and its potential implications for the company’s risk profile and long term earnings power. Analyst Commentary Recent commentary highlights that partial cannabis rescheduling is viewed as extremely favorable for the sector, but bearish analysts remain cautious on how much of that potential is already reflected in Aurora Cannabis' valuation at the current CA$5.00 price target.Narrativ-Update • Apr 20
ACB: Reset P E Multiple And Equity Issuance Will Shape Balanced Outlook
Analysts have reduced their CA$ price target on Aurora Cannabis by CA$1. This change reflects updated views on profit margins, revenue trends, and a lower assumed future P/E multiple.Narrativ-Update • Apr 05
ACB: Revised P E Assumptions And Policy Signals Will Guide Balanced Outlook
Aurora Cannabis' consensus analyst price target has been reduced by CA$1 as analysts factor in updated views on revenue trends, margin expectations, and a lower assumed future P/E multiple. Analyst Commentary Recent research updates point to a more cautious tone around Aurora Cannabis, as analysts reassess what they are willing to pay for the stock in light of current revenue and margin expectations.Narrativ-Update • Mar 22
ACB: Policy Shifts And Margin Efficiency Will Shape Cautious Yet Balanced Outlook
Aurora Cannabis' consensus analyst price target has been reduced by CA$1, as analysts adjust their models to reflect slightly lower revenue expectations, modestly higher profit margins, and a marginally lower future P/E multiple. Analyst Commentary Recent Street research around Aurora Cannabis reflects a more cautious tone on valuation and execution, even where overall views remain constructive.Narrativ-Update • Mar 07
ACB: Policy Shifts And Margin Execution Will Shape Fairly Balanced Outlook
Narrative update overview The latest analyst update trims the Aurora Cannabis price target by CA$1. This reflects a shift to lower expected profit margins and a higher assumed future P/E multiple, while still leaning on prior bullish initiation as support for the longer-term story.Narrativ-Update • Feb 21
ACB: Policy Shift And Execution Uncertainty Will Shape Balanced Risk Profile
Aurora Cannabis: Narrative Update Analysts reduced their 12-month price target for Aurora Cannabis by CA$1. This reflects updated expectations that now assume slightly softer revenue growth, somewhat higher profit margins, and a lower future P/E multiple.Narrativ-Update • Feb 06
ACB: Mixed Policy And Execution Signals Will Shape Risk Profile Ahead
Analysts have trimmed their fair value target for Aurora Cannabis from C$6.00 to C$5.00. This reflects an updated view that factors in a higher discount rate, revised revenue growth assumptions, improved profit margin expectations, and a lower future P/E multiple after recent Street research, including the latest Canaccord price target cut and an earlier bullish initiation.Analyseartikel • Nov 07
Aurora Cannabis Inc. (TSE:ACB) Stocks Pounded By 28% But Not Lagging Industry On Growth Or Pricing
Aurora Cannabis Inc. ( TSE:ACB ) shares have retraced a considerable 28% in the last month, reversing a fair amount of...Analyseartikel • Oct 03
Is Aurora Cannabis (TSE:ACB) Weighed On By Its Debt Load?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analyseartikel • Aug 29
Aurora Cannabis Inc. (TSE:ACB) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable
Aurora Cannabis Inc. ( TSE:ACB ) shares have had a really impressive month, gaining 27% after a shaky period...
Narrativ-Update • Aug 07
European And Australian Medical Cannabis Markets Will Unlock Enduring Potential
Despite substantial improvement in net profit margin and a sharply reduced future P/E ratio, the consensus analyst price target for Aurora Cannabis has decreased from CA$8.42 to CA$7.92. What's in the News Aurora Cannabis expects year-over-year net revenue growth in Q2 2026, primarily driven by an 8%–12% increase in its Global Medical Cannabis segment (Corporate Guidance – New/Confirmed, 2025-08-06).Analyseartikel • Jul 12
Aurora Cannabis Inc. (TSE:ACB) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Aurora Cannabis Inc. ( TSE:ACB ) shares have retraced a considerable 26% in the last month, reversing a fair amount of...Analyseartikel • Jun 26
Aurora Cannabis' (TSE:ACB) Earnings May Just Be The Starting Point
Investors were underwhelmed by the solid earnings posted by Aurora Cannabis Inc. ( TSE:ACB ) recently. We did some...Analyseartikel • May 23
After Leaping 29% Aurora Cannabis Inc. (TSE:ACB) Shares Are Not Flying Under The Radar
Those holding Aurora Cannabis Inc. ( TSE:ACB ) shares would be relieved that the share price has rebounded 29% in the...
Neues Narrativ • Apr 26
EU GMP And TGA Expertise Will Expand Global Cannabis Reach
Strategic international expansion and regulatory changes in key markets could significantly boost future revenues and medical cannabis margins.Analyseartikel • Feb 04
Investors Give Aurora Cannabis Inc. (TSE:ACB) Shares A 26% Hiding
Unfortunately for some shareholders, the Aurora Cannabis Inc. ( TSE:ACB ) share price has dived 26% in the last thirty...Analyseartikel • Nov 22
Aurora Cannabis Inc.'s (TSE:ACB) Share Price Is Still Matching Investor Opinion Despite 29% Slump
Aurora Cannabis Inc. ( TSE:ACB ) shareholders that were waiting for something to happen have been dealt a blow with a...Analyseartikel • Aug 02
It's Unlikely That Aurora Cannabis Inc.'s (TSE:ACB) CEO Will See A Huge Pay Rise This Year
Key Insights Aurora Cannabis to hold its Annual General Meeting on 9th of August Salary of CA$773.6k is part of CEO...Analyseartikel • Jun 27
Aurora Cannabis Inc.'s (TSE:ACB) Share Price Is Still Matching Investor Opinion Despite 29% Slump
Aurora Cannabis Inc. ( TSE:ACB ) shares have retraced a considerable 29% in the last month, reversing a fair amount of...Analyseartikel • Feb 15
Why Aurora Cannabis' (TSE:ACB) Earnings Are Weaker Than They Seem
We didn't see Aurora Cannabis Inc.'s ( TSE:ACB ) stock surge when it reported robust earnings recently. We decided to...Aktionärsrenditen
| ACB | CA Pharmaceuticals | CA Markt | |
|---|---|---|---|
| 7D | -3.1% | 6.9% | -2.5% |
| 1Y | -41.8% | 80.2% | 30.6% |
Rendite im Vergleich zur Industrie: ACB unter dem Niveau der Branche Canadian Pharmaceuticals , die im vergangenen Jahr eine Rendite von 80.2% erzielte.
Rendite vs. Markt: ACB hinter dem Markt Canadian zurück, der im vergangenen Jahr eine Rendite von 30.6 erzielte.
Preisvolatilität
| ACB volatility | |
|---|---|
| ACB Average Weekly Movement | 7.1% |
| Pharmaceuticals Industry Average Movement | 11.1% |
| Market Average Movement | 10.1% |
| 10% most volatile stocks in CA Market | 17.6% |
| 10% least volatile stocks in CA Market | 3.8% |
Stabiler Aktienkurs: ACB hatte in den letzten 3 Monaten im Vergleich zum Canadian -Markt keine signifikante Preisvolatilität.
Volatilität im Zeitverlauf: ACBDie wöchentliche Volatilität (7%) ist im vergangenen Jahr stabil geblieben.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 2013 | n/a | Miguel Martin | www.auroramj.com |
Aurora Cannabis Inc. ist zusammen mit seinen Tochtergesellschaften in der Produktion, dem Vertrieb und dem Verkauf von Cannabis und Cannabisderivaten in Kanada und international tätig. Das Unternehmen ist in zwei Segmenten tätig: Canadian Cannabis und Plant Propagation. Das Unternehmen bietet medizinische und Konsum-Cannabisprodukte an, liefert vermehrtes Gemüse und Zierpflanzen und vertreibt und verkauft aus Hanf gewonnene Cannabidiol (CBD)-Produkte.
Aurora Cannabis Inc.'s Grundlagenzusammenfassung
| ACB grundlegende Statistiken | |
|---|---|
| Marktanteil | CA$282.03m |
| Gewinn(TTM) | -CA$83.51m |
| Umsatz(TTM) | CA$373.12m |
0.7x
Kurs-Umsatz-Verhältnis-3.3x
Kurs-Gewinn-Verhältnis Ist ACB zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| ACB Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | CA$373.12m |
| Kosten der Einnahmen | CA$238.69m |
| Bruttogewinn | CA$134.43m |
| Sonstige Ausgaben | CA$217.94m |
| Gewinn | -CA$83.51m |
Zuletzt gemeldete Gewinne
Dec 31, 2025
Datum des nächsten Gewinnberichts
Jun 11, 2026
| Gewinn per Aktie (EPS) | -1.41 |
| Bruttomarge | 36.03% |
| Nettogewinnspanne | -22.38% |
| Schulden/Eigenkapital-Verhältnis | 10.9% |
Wie hat sich ACB auf lange Sicht entwickelt?
Historische Performance und VergleicheUnternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/06/09 13:15 |
| Aktienkurs zum Tagesende | 2026/06/09 00:00 |
| Gewinne | 2025/12/31 |
| Jährliche Einnahmen | 2025/03/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Aurora Cannabis Inc. wird von 17 Analysten beobachtet. 5 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Frederico Yokota Choucair Gomes | ATB Cormark |
| Tamy Chen | BMO Capital Markets Equity Research |
| Etienne Ricard | BMO Capital Markets Equity Research |